Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 6/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710925 | 0.85 | NR4A2 (0.40) | HCAR2DHODHIDO1ABCG2KDM4E | |
| SCHEMBL6718657 | 0.73 | NR4A2 (0.41) | HCAR2DHODHIDO1ABCG2 | |
| SCHEMBL6794325 | 0.73 | HCAR2 (0.40) | HCAR2DHODHIDO1ABCG2PARP1 | |
| SCHEMBL24604916 | 0.71 | DHODH (0.41) | HCAR2DHODHABCG2KDM4EALDH1A1 | |
| SCHEMBL15346406 | 0.71 | HCAR2 (0.46) | HCAR2DHODHABCG2KDM4EALDH1A1 | |
| SCHEMBL26859106 | 0.68 | HCAR2 (0.41) | HCAR2DHODHIDO1ABCG2ACHE | |
| Ethane SCHEMBL27315969 | 0.63 | ALDH1A1 (0.60) | KDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL18805060 | 0.63 | NPC1 (0.63) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2170490 | 0.63 | NPC1 (0.63) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6710746 | 0.62 | IDO1 (0.42) | HCAR2DHODHIDO1ABCG2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | JOHNSON BARRY L (US) | 2004-01-01 | — | — | US | disclosed |
| US-6593337-B1 | pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | POLRMT, TYMP, POLM | HCAR2 3735/4885DHODH 48/4885IDO1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.